Prescription-grade AlnayaSN™ (Nicotinic Acid / Niacin 500mg) is an FDA-approved therapeutic indicated for managing severe dyslipidemia and treating profound systemic niacin deficiency (pellagra).
In Global Oncology and Global Pathology settings, patients frequently face metabolic collapse from tumor-induced nutrient theft, cancer cachexia, chemotherapy side effects, and septic shock. The AlnayaSN™ Software Suite serves as an advanced Clinical Decision Support System (CDSS). It allows medical teams to evaluate cellular energy dynamics and track multi-year patient trajectories under progressive nicotinic acid protocols.
- NAD+ Replenishment: AlnayaSN™ serves as the direct biochemical precursor for Nicotinamide Adenine Dinucleotide (NAD+). Aggressive malignancies and systemic viral infections act as metabolic parasites, rapidly depleting host cellular NAD+ reserves to fuel replication.
- DNA Repair Integrity: Restoring NAD+ levels reactivates crucial poly(ADP-ribose) polymerase (PARP-1) enzymes. In severe pellagra, PARP-1 failure prevents the repair of UV-induced DNA breaks, directly driving pellagra dermatitis and elevating the risk of secondary non-melanoma skin malignancies (Squamous Cell Carcinoma).
- Neurological Stability: Maintaining standard NAD+ availability protects central nervous system tissue from pellagrous encephalopathy, mitigating risks of cognitive decline, dementia, muscle rigidity, and toxic psychosis.
- Anti-Lipolysis (GPR109A Activation): AlnayaSN™ binds to G-protein coupled receptors (GPR109A) on adipocytes, suppressing hormone-sensitive lipase (HSL). This cuts off the flow of free fatty acids to the liver, causing a sharp reduction in very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL, or "bad" cholesterol).
- Triglyceride Synthesis Blockade: Inside hepatic tissue, nicotinic acid directly inhibits the DGAT2 enzyme, slowing down internal triglyceride construction.
-
Mitochondrial Fat Oxidation (Thermogenesis): AlnayaSN™ activates Brown Adipose Tissue (BAT) by upregulating Uncoupling Protein-1 (UCP1). This shifts cells from standard energy production to internal lipid burning, forcing fat mass destruction. According to strict thermodynamic laws, 84% of degraded fat mass is converted into gas and exhaled through the lungs as Carbon Dioxide (
$CO_2$ ), while 16% becomes metabolic water ($H_2O$ ).
-
Mucosal Hyper-motility: High therapeutic doses of AlnayaSN™ can cause a localized prostaglandin surge (
$PGD_2$ ) in the intestinal lining. This irritation accelerates intestinal contractions, pushing food through too quickly for proper enzyme breakdown. - Induced Steatorrhea: This hyper-motility disrupts bile emulsification, causing a drop in the Coefficient of Fat Absorption (COA). Dietary fats pass completely unabsorbed into the feces, presenting clinically as greasy, lard-like stools (steatorrhea).
The integrated Python tracking application allows clinicians to input custom patient biometrics and baseline blood gas metrics to project a 3-year timeline of metabolic accumulation, Nernstian electrical shifts, and fat-burning mechanics.
The U.S. Food and Drug Administration (FDA) allows prescription AlnayaSN (Nicotinic Acid / Niacin) for managing abnormal cholesterol levels (dyslipidemia) and preventing or treating severe niacin deficiency (pellagra).
This repository contains a Python-based quantitative simulation engine designed to model multi-year tracking of systemic pH, negative charge density, Nernstian potentials, and lipid modifications under progressive high-dose nicotinic acid protocols across varied clinical profiles (healthy, cancer-induced acidosis, and septic crisis).
Models a continuous 3-year timeline (1095 days) mapping a patient's physical attributes to a deterministic charge-density timeline:
- Volumetric Scaling: Uses the Watson Formula to compute baseline total body water volume scaled by customizable build and hydration variables.
- Pathological Deficit Scaling: Automatically degrades daily compound clearance rates and exhausts bicarbonate buffer parameters based on custom initial arterial blood gas (ABG) pH entries.
- Electromotive Mapping: Applies the Nernst Equation derivative (-61.5 mV per pH unit shift at 37°C) to track changes in the electrical reduction potential of free proton availability.
Rejects sweat-loss fallacies and enforces strict thermodynamic laws regarding lipid mass displacement:
- Stoichiometric Burning: Tracks the chemical breakdown of body fat droplets via mitochondrial beta-oxidation (C₅₅H₁₀₄O₆ + 78O₂ → 55CO₂ + 52H₂O), mapping out that 84% of lost fat mass is exhaled exclusively via the lungs as Carbon Dioxide gas.
- Niacin-Induced Thermogenesis: Models Brown Adipose Tissue (BAT) activation and Uncoupling Protein-1 (UCP1) upregulation to track accelerated cellular lipid burning.
Simulates circulating blood lipid changes versus gastrointestinal side effects:
- Lipid Profiles: Tracks expected clinical drops in Low-Density Lipoproteins (LDL) and Triglycerides via GPR109A receptor binding and hepatic DGAT2 enzyme inhibition.
- Fecal Fat Excretion: Incorporates a progressive drop in the Coefficient of Fat Absorption (COA) during high-dose mucosal hyper-motility, plotting the clinical onset of severe secondary steatorrhea (oily, lard-like stools).
The scripts run on native Python 3 and require standard data-science plotting and analysis libraries:
pip install numpy pandas matplotlibAlnayaSN-500mg/
├── src/
│ ├── unified_simulator.py # Core biometric, pH, and Nernstian tracking script
│ └── lipid_oxidation_model.py # True fat oxidation and fecal fat excretion tracker
├── docs/
│ ├── Electrochemistry_pH.md # Thermodynamic derivations of Nernstian slope equations
│ └── Lipid_Metabolism.md # Hepatic enzyme blocks and GPR109A pathway data
├── LICENSE # BSL-1.0 License
└── README.md # Main repository documentation
This project is licensed under the terms of the Boost Software License 1.0 (BSL-1.0) - see the LICENSE file for details.
The software contained within this repository represents a theoretical physics and chemical abstraction modeling un-neutralized molecular dissociation in an isolated system. It does not reflect real-time live human clinical biology or homeostatic respiratory compensation pathways.
The Food and Nutrition Board establishes the adult Tolerable Upper Intake Level (UL) for niacin at 35 mg per day. High-dose prescription AlnayaSN (500mg) protocols significantly exceed standard nutritional upper limits, carry strict risks of severe hepatotoxicity, skin flushing, or metabolic shifts, and must strictly be managed under direct clinical oversight from a licensed medical professional.